8
Oct
2024

ZHEJIANG LANGHUA PHARMACEUTICAL CO., LTD

Exhibitor at CPHI Milan 2024 stand 3D41, API
About Us

Langhua Pharma,FDA, WHO, EDQM, ANVISA and NMPA approved manufacturer in China.Producing APIs, intermediates and Delivering CDMO projects. 
Robust GMP
Strong EHS
Experienced filing in the regulated markets.

  • CN
  • 2015
    On CPHI since
  • 3
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Custom Manufacturing/Custom Synthesis
Contact info
  • Zhejiang Provincial Chemical and Medical Material , Base Linhai Zone, 317016, Taizhou, Zhejiang, China
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 3D41, API

Products Featured at CPHI Milan 2024

  • Spironolactone

    Product Spironolactone

    cardiovascular system drugs CEP and USDMF registered
  • Enrofloxacin

    Product Enrofloxacin

    Third generation Quinolones antibacterial products, veterinary use CEP and USDMF registered
  • Levofloxacin Hemihydrate

    Product Levofloxacin Hemihydrate

    Quinolones antibacterial product, anti-infective CEP , USDMF registered
  • Ciprofloxacin Hydrochloride

    Product Ciprofloxacin Hydrochloride

    Wide-range antibacterial
  • Canrenone

    Product Canrenone

    Intermediate grade: Assay: NLT 90%; NLT 97%. 
    API grade